VitaFlow Liberty^®'s groundbreaking breakthrough upgraded delivery system, adding the retrievable function combined with the world’s first double reinforced spiral design on the basis of the electric handle, which achieves the flexibility and 360°range of motion, while ensuring fast, stable and precise release and recapture.

Currently, MicroPort^® CardioFlow 's products have entered several overseas markets such as Colombia, Argentina, Brazil and Thailand.

Shanghai, China - MicroPort^® CardioFlow Medtech Corporation ("MicroPort^® CardioFlow", stock code: 02160.HK) recently announced that its self-developed VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System ("VitaFlow Liberty^®") and Alwide^® Plus Balloon Catheter ("Alwide^® Plus") have been approved for registration by the Thailand Food and Drug Administration (Thai FDA).

VitaFlow Liberty^® is the world’s only electric retrievable transcatheter aortic valve system, offering outstanding stability during procedure and hemodynamics post-procedure that will improve the quality of life for patients with aortic valve disease. It inherits the advantages of the VitaFlow^® in terms of valve design, featuring a hybrid density self-expanding stent, bovine pericardial leaflets, and a high double-layer PET skirt design. This design offers robust radial force, improved coaxiality during deployment, and effectively reduces the incidence of perivalvular leakage post-procedure. Moreover, its breakthrough upgraded delivery system incorporates a unique and innovative double-reinforced spiral structure that ensures rapid, stable, and precise release and retrieval. This system also provides flexibility, allowing for 360-degree bending of the valve segment.

As an upgrade product of Alwide^® Balloon Catheter ("Alwide^®"), Alwide^® Plus obtained marketing approval from the National Medical Products Administration (NMPA) of China in July 2021. The low compliance of Alwide^® Plus allows for more accurate balloon expansion size, the high burst pressure will better respond to the patient's high calcification, and its rapid filling and retraction features reduce pacing time. In addition, Alwide^® Plus has significantly improved puncture resistance, which is designed to provide the surgeon with a better experience while further increasing the safety of intraoperative balloon expansion.

Previously, MicroPort^® CardioFlow's transcatheter aortic valve products and its accessory product VitaFlow^® and Alwide^® had been approved for marketing in Thailand. At present, MicroPort^® CardioFlow has achieved multiple products entering markets in four countries including Colombia, Argentina, Brazil, and Thailand, and will continue to actively promote the expansion of the global market and innovative research and development in the future, to bring high-quality, universal total solutions for structural heart disease to more patients around the world.